

## Follow-Up Care for Children Prescribed ADHD Medication for Attention Deficit Disorder (ADD)

### Patient Profile

MVP members 6–12 years of age newly prescribed Attention-Deficit/Hyperactivity Disorder (ADHD) medication. These patients will need at least three follow-up care visits within a 10-month period. The initial visit must occur within the first 30 days of the prescription dispensing date.

**Note:** Telehealth visits, e-visits, and virtual check-ins count for the initiation and continuous phase for this measure.

### How to Implement Best Practices and Improve Performance

- Once medication treatment has been established, you need to conduct parent or guardian education and include the child as much as possible.
- Understanding what the medication is going to do and how it will make them feel is an important part of establishing awareness and ensuring better compliance. You must discuss potential side effects and how they should respond if they occur. Communicate that there will be no medication refills until the initial follow-up visit is complete. Instruct office staff that if any appointment is canceled, it must be rescheduled at the time of cancellation.
- Make sure the parent or guardian understands the instructions in order to achieve better drug compliance.
- Set up a follow-up visit plan with the parent or guardian, and child if necessary. Establish this visit within 2–3 weeks of the initial medication therapy. Once the child attends the initial follow-up visit, schedule the additional two visits within nine months of the start of the medication. Ask questions in order to assess the child’s response to the medication, as it is often necessary to adjust to establish the correct dosage.
- Encourage a parent/teacher conference and include the school nurse. Use of the Vanderbilt Assessment Scale by both the family and the school may be helpful during follow-up visits to see how a child is responding to the medication. At each visit, assess the child for other referrals as needed, such as a Behaviorist or Child Psychologist.
- Refer parents or guardians to [aap.org](http://aap.org) or [cdc.gov](http://cdc.gov) for further educational information regarding ADHD.

*Information related to all 2021 HEDIS measures has been extracted from the NCQA 2021 HEDIS Technical Specifications Volume 2.*

### ADHD Medications

<b>CNS Stimulant Medications</b>	Amphetamine-dextroamphetamine Methamphetamine	Dextroamphetamine Dexmethylphenidate	Methylphenidate Lisdexamfetamine
<b>Alpha-2 Receptor Agents</b>	Clonidine	Guanfacine	
<b>Miscellaneous ADHD Medications</b>	Atomoxetine		

*Use of drugs listed here will score the measure as compliant. Remember to reference the MVP Formulary to learn which of these medications are covered by the member’s plan. For information on medications covered by MVP, see the MVP Medicaid Drug Formulary available by visiting [mvphhealthcare.com](http://mvphhealthcare.com) and selecting Providers, then Pharmacy, then MVP Formularies.*

<b>2021 Coding for Follow-Up Care for Children Prescribed ADHD Medication for Attention Deficit Disorder (ADD)</b>	
<b>Codes for ADD- Initiation Phase</b>	<b>Use of any of the following codes billed by a provider with prescribing authority will meet criteria for the initiation phase for ADD.</b>
<b>BH Outpatient</b>	<b>CPT:</b> 98960-98962, 99078, 99201-99205, 99211-99215, 99241-99245, 99341-99345, 99347-99350, 99381-99387, 99391-99397, 99401-99404, 99411-99412, 99510
	<b>HCPCS:</b> G0155, G0176-G0177, G0409, G0463, H0002, H0004, H0031, H0034, H0036, H0037, H0039, H0040, H2000, H2010-H2011, H2013-H2021, M0064, T1015
	<b>SNOMED CT US:</b> 17436001, 30346009, 37894004, 77406008, 84251009, 185463005, 185464004, 185465003, 281036007, 391223001, 391224007, 391225008, 391237005, 391239008, 391242002, 391257009, 391260002, 391261003, 439740005, 3391000175108, 444971000124105
	<b>UB Rev:</b> 0510, 0513, 0515-0517, 0519-0523, 0526-0529, 0900, 0902-0904, 0911, 0914-0917, 0919, 0982-0983
<b>Community Mental Health Center POS</b>	<b>POS:</b> 53
<b>Health and Behavior Assessment/ Intervention</b>	<b>CPT:</b> 96150-96154
<b>Observation</b>	<b>CPT:</b> 99217-99220
<b>Outpatient POS</b>	<b>POS:</b> 03, 05, 07, 09, 11-20, 22, 33, 49, 50, 71-72
<b>Partial Hospitalization POS</b>	<b>POS:</b> 52
<b>Partial Hospitalization/Intensive Outpatient</b>	<b>HCPCS:</b> G0410, G0411, H0035, H2001, H2012, S0201, S9480, S9484, S9485
	<b>SNOMED CT US:</b> 7133001, 305345009, 305346005, 305347001, 391038005, 391042008, 391043003, 391046006, 391047002, 391048007, 391054008, 391055009, 391056005, 391133003, 391150001, 391151002, 391152009, 391153004, 391170007, 391185001, 391186000, 391187009, 391188004, 391191004, 391192006, 391194007, 391195008, 391207001, 391208006, 391209003, 391210008, 391211007, 391223001, 391226009, 391228005, 391229002, 391232004, 391233009, 391237005, 391252003, 391254002, 391255001, 391256000, 391257009
	<b>UB Rev:</b> 0905, 0907, 0912, 0913
<b>Visit Setting Unspecified</b>	<b>CPT:</b> 90791, 90792, 90832-90834, 90836-90840, 90845, 90847, 90849, 90853, 90875, 90876, 99221-99223, 99231-99233, 99238, 99239, 99251-99255
<b>Codes for ADD- Continuation and Maintenance Phase</b>	<b>Use of any of the above codes billed by a provider with prescribing authority, as well as any of the following codes, will meet criteria for the Continuation and Maintenance Phase for ADD.</b>
<b>Telephone Modifier</b>	<b>CPT:</b> 95, GT
<b>Telephone POS</b>	<b>POS:</b> 02
<b>Telephone Visits</b>	<b>CPT:</b> 98966-98968, 99441-99443
	<b>SNOMED CT US:</b> 85317003, 314849005, 386472008, 386473003, 38647900

<b>2021 Coding for Follow-Up Care for Children Prescribed ADHD Medication for Attention Deficit Disorder (ADD) (continued)</b>	
<b>Exclusions from ADD</b>	<b>The following codes excludes members from passing this measure.</b>
<b>Acute Inpatient</b>	<b>CPT:</b> 99221-99223, 99231-99233, 99238, 99239, 99251-99255, 99291
	<b>HCPCS:</b> G9474-79, Q5003-8, Q5010, S9126, T2042-6
<b>Hospice Encounter</b>	<b>SNOMED CT US:</b> 183919006, 183920000, 183921001, 305336008, 305911006
	<b>UB Rev:</b> 0115, 0125, 0135, 0145, 0155, 0235, 0650-52, 0655-59
<b>Hospice Intervention</b>	<b>CPT:</b> 99377-8
	<b>SNOMED CT US:</b> 170935008, 170936009
	<b>HCPCS:</b> G08182
<b>Inpatient Stay</b>	<b>UB Rev:</b> 0100-0101, 0110-0114, 0116-0124, 0126-0134, 0136-0144, 0146-0154, 0156-0160, 0164, 0167, 0169-0174, 0179, 0190-0194, 0199-0204, 0206-0214, 0219, 1000-1002
<b>Long Acting Injections 14-Day Supply</b>	<b>HCPCS:</b> J2794
<b>Long Acting Injections 28-Day Supply</b>	<b>HCPCS:</b> J0401, J1631, J2358, J2426, J2680, C9035
<b>Long Acting Injections 30-Day Supply</b>	<b>HCPCS:</b> C9037
<b>Mental, Behavioral and Neurodevelopmental Disorders</b>	<b>ICD-10 CM:</b> F01-F99
<b>Narcolepsy</b>	<b>ICD-10 CM:</b> G47.411, G47.419, G47.421, G47.429
	<b>SNOMED CT US:</b> 60380001, 193042000, 427426006, 735676003, 91521000119104, 434241000124107, 434251000124109, 434261000124106
<b>Non-acute Inpatient</b>	<b>CPT:</b> 99318, 99304-10, 99315-16, 99324-28, 99334-37
<b>Non-acute Inpatient Stay</b>	<b>UB Rev:</b> 0022, 0024, 0118, 0128, 0138, 0148, 0158, 0190-0194, 0199, 0524, 0525, 0550-0552, 0559, 0660-0663, 0669, 1000-1002
<b>Frailty Symptom</b>	<b>ICD-10 CM:</b> R26.0-R26.2, R26.89, R26.9, R41.81, R53.1, R53.81, R53.83, R54, R62.7, R63.4, R63.6, R64
<b>Hospice Encounter</b>	<b>HCPCS:</b> G9474-79, Q5003-8, Q5010, S9126, T2042-6
	<b>UB Rev:</b> 0115, 0125, 0135, 0145, 0155, 0235, 0650-52, 0655-59
<b>Hospice Intervention</b>	<b>CPT:</b> 99377-8
	<b>HCPCS:</b> G08182
<b>Inpatient Stay</b>	<b>UB Rev:</b> 0100-0101, 0110-0114, 0116-0124, 0126-0134, 0136-0144, 0146-0154, 0156-0160, 0164, 0167, 0169-0174, 0179, 0190-0194, 0199-0204, 0206-0214, 0219, 1000-1002